[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100485488":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":30,"centralContacts":34,"locations":44,"responsibleParty":88,"collaborators":39,"id":90,"slug":91,"hasResults":92,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":96,"eligibilityCriteria":97,"healthyVolunteers":92,"sex":98,"minAge":99,"maxAge":39,"enrollmentInfo":100,"targetDuration":39,"studyType":103,"phases":104,"briefSummary":107,"conditions":108,"keywords":111,"overallStatus":47,"whyStopped":39,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":123},{"fullName":5,"class":6},"Advanced BioDesign","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Single Administration Dose (SAD) of ABD-3001","EXPERIMENTAL","Dose escalation of 6 doses level using a 3+3 design.",[13],"Drug: ABD-3001",{"label":15,"type":10,"description":16,"interventionNames":17},"Multiple Administration Dose (MAD) of ABD-3001","3 doses regimens in parallel during 3 cycles of 28 days",[13],[19,26],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","ABD-3001","Each patient will receive a fixed 4 hours-intravenous infusion dose of ABD-3001 once or twice a week.\n\nFor SAD : The first dose of the first cohort will receive an estimated infusion dose of 18 mg\u002Fm² at Day 1. Subsequent cohorts will be given the following doses: 54 mg\u002Fm², 135 mg\u002Fm², 270 mg\u002Fm², 405 mg\u002Fm², 540 mg\u002Fm².",[9],[25],"DIMATE",{"type":20,"name":21,"description":27,"armGroupLabels":28,"otherNames":29},"For MAD :\n\nBased on all data gathered during the SAD including safety, PK and preliminary efficacy data, up to three doses were selected in accordance with the Safety review Committee (SRC). A dosage optimization analysis was performed at the end of the SAD cohort 6 using population pharmacokinetic modelling to set the optimal frequency of infusion per week for each selected dose to achieve sustained exposition throughout the treatment period. Based on this analysis, the Sponsor, in agreement with the SRC, defined 3 doses regimens that will be set up in parallel, with infusion of ABD-3001 once or twice a week during 3 cycles of 28 days.",[15],[25],[31],{"name":32,"affiliation":5,"role":33},"Laurent BASSET","STUDY_DIRECTOR",[35,41],{"name":36,"role":37,"phone":38,"phoneExt":39,"email":40},"Guillaume MARTIN","CONTACT","+33 (4) 82 53 89 62",null,"guillaume.martin@a-biodesign.com",{"name":32,"role":37,"phone":42,"phoneExt":39,"email":43},"+33 (0)4 28 29 46 78","laurent.basset@a-biodesign.com",[45,62,75],{"facility":46,"status":47,"city":48,"state":49,"zip":50,"country":49,"countryCode":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":58},"Hôpital de la Timone","RECRUITING","Marseille","France","13005","FR",{"type":53,"coordinates":54},"Point",[55,56],5.38107,43.29695,{"lat":56,"lon":55},[59],{"name":60,"role":37,"phone":39,"phoneExt":39,"email":61},"Régis COSTELLO","regis.costello@ap-hm.fr",{"facility":63,"status":47,"city":64,"state":49,"zip":65,"country":49,"countryCode":51,"cosmosGeoPoint":66,"geoPoint":70,"contacts":71},"Hôpital Saint-Louis","Paris","75475",{"type":53,"coordinates":67},[68,69],2.3488,48.85341,{"lat":69,"lon":68},[72],{"name":73,"role":37,"phone":39,"phoneExt":39,"email":74},"Lina BENAJIBA","lina.benajiba@aphp.fr",{"facility":76,"status":47,"city":77,"state":49,"zip":78,"country":49,"countryCode":51,"cosmosGeoPoint":79,"geoPoint":83,"contacts":84},"Centre Hospitalier Lyon Sud","Pierre-Bénite","69495",{"type":53,"coordinates":80},[81,82],4.82424,45.70359,{"lat":82,"lon":81},[85],{"name":86,"role":37,"phone":39,"phoneExt":39,"email":87},"Maël HEIBLIG","mael.heiblig@chu-lyon.fr",{"type":89,"investigatorFullName":39,"investigatorTitle":39,"investigatorAffiliation":39,"oldNameTitle":39,"oldOrganization":39},"SPONSOR","100485488","phase-1-first-in-human-study-aiming-to-characterize-the-safety-tolerability-pharmacokinetic-and-preliminary-signs-of-activity-of-abd-3001-in-refractory-or-relapsed-aml-and-high-risk-mds-adult-patients-100485488",false,"NCT05601726","First-in-human Study Aiming to Characterize the Safety, Tolerability, Pharmacokinetic and Preliminary Signs of Activity of ABD-3001 in Refractory or Relapsed AML and High Risk MDS Adult Patients","First-In-Human, Open Label, Dose Escalation Study to Evaluate Safety, PK and PD of ABD-3001 As Monotherapy in Relapsed\u002FRefractory Acute Myeloid Leukemia or High\u002FVery-high Risk Myelodysplastic Syndromes Patients, Ineligible for Intensive or New Generation Targeted Therapy.","ODYSSEY","Inclusion Criteria:\n\n* Patients with relapsed\u002Frefractory Acute Myeloid Leukemia (AML) after failing at least one therapy regimen and a salvage treatment or are not eligible for salvage treatment regimens including targeted therapy\n* Patients with relapsed\u002Frefractory Myelodysplastic syndrome (MDS) ineligible for salvage treatment who are diagnosed high-risk and very high-risk using Revised International Prognostic Scoring System (IPSS-R) prognostic risk categorization\n* Patients not eligible to alloSCT\n* Negative blood or serum\u002Furine pregnancy test\n\nExclusion Criteria:\n\n* Patients with acute myeloid leukemia (AML) with Inv(16) MYH11-CBF-Beta or t(8;21) AML-ETO RUNX1-RUNX1 or (PML\u002FRARA) karyotype abnormalities and eligible to targeted therapies\n* Participants with clinical symptoms suggestive of active central nervous system (CNS) leukemia or known CNS leukemia\n* Ongoing immunosuppressive treatment\n* Hematopoietic stem cell transplantation (HSCT) performed within 3 months prior to study Visit 1\n* Active infection requiring intravenous anti-infectious treatment during the screening period\n* Life-threatening illnesses other than the studied one, uncontrolled medical conditions or organ system dysfunction which, in the investigator's opinion, could compromise the patient's safety or interfere with the patient's ability to comply with the study activities\n* Anti-tumor therapy within 14 days of study Visit 1\n* Prior participation in an interventional investigational clinical study (drug or medical device) within 21 days of study Visit 1\n* Radiotherapy within 28 days prior to study Visit 1\n* Current history of seropositivity to human immunodeficiency virus (HIV) or infection with active hepatitis C virus (HCV) or active hepatitis B virus (HBV) or active SARS-CoV-2 (Covid-19) or Syphilis, or Cytomegalovirus (CMV), or Epstein-Barr virus (EBV), or Human T-Lymphotropic Virus (HTLV1)\n* History of other malignancy in the last 12 months prior to study Visit 1\n* Other active solid tumor\n* Subjects with New York Heart Association (NYHA) Class III or IV congestive heart failure or Left Ventricular Ejection Fraction (LVEF) \\\u003C50% attested by echocardiogram (ECHO) or multi-gated acquisition (MUGA) scan within 28 days of C1D1 prior to study Visit 1 (Day 1, start of study therapy)\n* Subjects with a history of myocardial infarction within the last 3 months prior to study Visit 1 (Day 1, start of study therapy)\n* Subjects with heart-rate corrected QT (QTc) interval ≥450 ms or other factors that increase the risk of QT prolongation or arrhythmic events\n* Major surgery within 4 weeks prior to study Visit 1 (Day 1, start of study therapy)\n* Any condition deemed by the investigator to be likely to interfere with a subject's ability to participate in the clinical trial MAD specific exclusion criteria: Patients who have been part of SAD and have experienced a DLT.","ALL","18 Years",{"count":101,"type":102},36,"ESTIMATED","INTERVENTIONAL",[105,106],"PHASE1","PHASE2","This First In Human (FIH) study is a prospective, open-label, multicenter, Phase 1 study, with a dose escalation design, followed by an optimized design. It will consist in a Single Ascending Dose (SAD) part and a Multiple Ascending Dose (MAD) part.",[109,110],"Acute Myeloid Leukemia, Adult","Myelodysplastic Syndromes",[109,112,113,21],"Myelodysplastic syndromes","First in Human","2025-01-17",{"date":116,"type":117},"2025-01-20","ACTUAL",{"date":119,"type":117},"2022-11-08",{"date":121,"type":102},"2026-12",{"name":5,"class":6},3]